Top

Published in:

01-04-2019 | Schizophrenia | Original Article

Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia

Authors: H. K. Luckhoff, S. Kilian, M. R. Olivier, L. Phahladira, F. Scheffler, S. du Plessis, B. Chiliza, L. Asmal, R. Emsley

Published in: Metabolic Brain Disease | Issue 2/2019

Abstract

Few studies have investigated the longitudinal effects of treatment-emergent metabolic syndrome changes on cognitive performance in first-episode psychosis. The aim of the present study was to determine the associations between changes in metabolic syndrome constituent component over 12 months of treatment and end-point cognitive performance in schizophrenia spectrum disorders. This single site-cohort study included 72 minimally treated or antipsychotic-naïve first-episode patients. Cognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). Our primary objective of interest was the relationship between metabolic syndrome constituent component changes over 12 months of treatment and end-point cognitive performance. Secondary objectives included investigating whether this relationship was affected by age, sex, antipsychotic dose, treatment duration and substance use. Weight gain predicted better overall cognition (p = 0.02) at end-point, adjusting for age, sex, substance use, baseline cognitive score and BMI, modal antipsychotic dose and treatment duration. Weight loss (p = 0.04) and substance use (p = 0.01) were both associated with poorer working memory performance at end-point. Low baseline BMI showed differential effects on end-point working memory performance in substance users (unfavorable) compared to non-users (favorable) (p < 0.05). In conclusion, weight gain over the course of antipsychotic treatment is associated with better overall cognitive performance and the working memory domain in first-episode schizophrenia spectrum disorder patients. In contrast, low baseline BMI may represent an unfavorable marker in substance users, who demonstrated weight loss compared to non-users.

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM). Washington DC: American Psychiatric Association

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62(4):231–238PubMedCrossRef

Bogaty SER, Lee RSC, Hickie IB, Hermens DF (2018) Meta-analysis of neurocognition in young psychosis patients with current cannabis use. J Psychiatr Res 99:22–32PubMedCrossRef

Bora E (2016) Differences in cognitive impairment between schizophrenia and bipolar disorder: considering the role of heterogeneity. Psychiatry Clin Neurosci 70(10):424–433PubMedCrossRef

Bora E, Akdede BB, Alptekin K (2017a) Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med 47(14):2401–2413PubMedCrossRef

Bora E, Akdede BB, Alptekin K (2017b) The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med 47(6):1030–1040PubMedCrossRef

Botis AC, Miclutia I, Vlasin N (2016) Cognitive function in female patients with schizophrenia and metabolic syndrome. Eur Psychiatry 33:97CrossRef

Boyer L, Richieri R, Dassa D, Boucekine M, Fernandez J, Vaillant F, Padovani R, Auquier P, Lancon C (2013) Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Res 210(2):381–386PubMedCrossRef

Chiliza B, Asmal L, Oosthuizen P, van Niekerk E, Erasmus R, Kidd M, Malhotra A, Emsley R (2015) Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. Eur Psychiatry 30(2):277–283PubMedCrossRef

Chukhin E, Terevnikov V, Takala P, Hakko H, Putkonen H, Räsänen P, Stenberg JH, Eronen M, Joffe G (2016) Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism? Nord J Psychiatry 70(3):190–194PubMedCrossRef

Dickinson D, Harvey PD (2009) Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 35(2):403–414PubMedCrossRef

Elias PK, Elias MF, D'Agostino RB, Sullivan LM, Wolf PA (2005) Serum cholesterol and cognitive performance in the Framingham heart study. Psychosom Med 67(1):24–30PubMedCrossRef

First MB, Spitzer RLGM, Williams LBW (1994) Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). In (Anonymous), New York State Psychiatric Institute, Biometrics Research: New York

Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL (2010) The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 167(10):1232–1239PubMedCrossRef

Girgis RR, Javitch JA, Lieberman JA (2008) Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 13(10):018–929CrossRef

Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N (2015) Associations between components of metabolic syndrome and cognition in patients with schizophrenia. J Psychiatr Pract 21(3):190–197PubMedCrossRef

Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J (2013) The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry 13:109PubMedPubMedCentralCrossRef

Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA (2011) Serotonergic anti-obesity agents: past experience and future prospects. Drugs 71(17):2247–2255PubMedCrossRef

Higgs S, Spetter MS (2018) Cognitive control of eating: the role of memory in appetite and weight gain. Curr Obes Rep 7:50–59PubMedPubMedCentralCrossRef

Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25(3):25–258CrossRef

Krakowski M, Czobor P (2011) Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res 130(1–3):27–33PubMedCrossRef

Lindenmayer JP, Khan A, Kaushik S, Thanju A, Praveen R, Hoffman L, Cherath L, Valdez G, Wance D (2012) Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res 142(1–3):171–176PubMedCrossRef

Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8(3):218–226PubMedCrossRef

Luckhoff H, Phahladira L, Scheffler F, Asmal L, du Plessis S, Chiliza B, Kilian S, Emsley R (2018) Weight gain and metabolic change as predictors of symptom improvement in fist-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophrenia Research pii: S0920-9964(18)30682-0

McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, Eggleston A (2003) Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measures Study in Schizophrenia. Can J Psychiatr 48(10):689–694CrossRef

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull 39(2):306–318PubMedCrossRef

Nasrallah H, Blom TJ (2015) Elevated cholesterol and triglycerides are associated with better cognitive functioning in schizophrenia: data from the CATIE study. Presentation at: APA 2015. May 16-20, 2015; Toronto, Canada

Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Paras L, Miller R (1999) Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 25(2):321–335PubMedCrossRef

Novick D, Haro JM, Suarez D, Lambert M, Lépine JP, Naber D (2007) Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berlin) 191(4):1015–1022CrossRef

Novick D, Haro JM, Suarez D, Vieta E, Naber D (2009) Recovery in the outpatient setting: 36-month results from the schizophrenia outpatients health outcomes (SOHO) study. Schizophr Res 108(1–3):223–230PubMedCrossRef

Nuechterlein KH, Green MF (2006) MATRICS consensus battery manual 2006. MATRICS Assessment Inc., Los Angeles

Olivier MR, Killian S, Chiliza B, Asmal L, Schoeman R, Oosthuizen PP, Kidd M, Emsley R (2015) Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychol Med 45(13):2873–2883PubMedCrossRef

Orosco M, Rouch C, Gerozissis K (2000) Activation of hypothalamic insulin by serotonin is the primary event of the insulin-serotonin interaction involved in the control of feeding. Brain Res 872(1–2):64–70PubMedCrossRef

Panariello F, Javaid N, Teo C, Monda M, Viggiano A, De Luca V (2011) The role of orexin system in antipsychotics induced weight gain. Curr Psychiatr Rev 7(1):18–21CrossRef

Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK (2018) The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neurosci 11:741PubMedPubMedCentralCrossRef

Sanchez-Gutierrez T, Fernandez-Castilla B, Barbeito S, Becerra JA, Calvo A (2018) Comparison between cannabis users and non-users patients with first-episode psychosis in neurocognitive functioning: a meta-analysis. Schizophr Bull 44(1):255–256CrossRef

Scheffler F, Kilian S, Chiliza B, Asmal L, Phahladira L, du Plessis S, Kidd M, Murray RM, Di Forti M, Seedat S, Emsley R (2018) Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders. Schizophr Res 199:90–95PubMedCrossRef

Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ (2006) Serotonin and human cognitive performance. Curr Pharm Des 12(20):2473–2486PubMedCrossRef

Shemesh E, Rudich A, Harman-Boehm I, Cukieman-Yaffe T (2012) Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 97(2):366–376PubMedCrossRef

Smith PJ, Blumenthal JA, Babyak MA, Craighead L, Welsh-Bohmer KA, Browndyke JN, Strauman TA, Sherwood A (2010) Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. Hypertension 55(6):1331–1338PubMedPubMedCentralCrossRef

Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J (2011) Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 187(1–2):42–48PubMedCrossRef

Storch-Jakobsen A, Speyer H, Nørgaard HCB, Hjorthøj C, Krogh J, Mors O, Nordentoft M (2018) Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - baseline and two-years findings from the CHANGE trial. Schizophr Res 199:96–102PubMedCrossRef

Strac D, Pivac N, Mück-Šeler D (2016) The serotonergic system and cognitive function. Transl Neurosci 7(1):35–49

Umbriaco D, Garcia S, Beaulieu C, Descarries L (1995) Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus 5(6):605–620PubMedCrossRef

Wiesbeck GA, Weijers HG, Wodarz N, Lesch OM, Glaser T, Boening J (2003) Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics. Arch Womens Ment Health 6:259–262PubMedCrossRef

Wysokinski A, Dzienniak M, Kłoszewska I (2013) Effect of metabolic abnormalities on cognitive performance and clinical symptoms in schizophrenia. Archives of Psychiatry and Psychotherapy 4:13–25CrossRef

Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2012) The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 38(2):316–330PubMedCrossRef

Title: Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia
Authors: H. K. Luckhoff
S. Kilian
M. R. Olivier
L. Phahladira
F. Scheffler
S. du Plessis
B. Chiliza
L. Asmal
R. Emsley
Publication date: 01-04-2019
Publisher: Springer US
Keyword: Schizophrenia
Published in: Metabolic Brain Disease / Issue 2/2019
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-018-0372-6

At a glance: The STEP trials

Springer Medicine

Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Neurons in rat orbitofrontal cortex and medial prefrontal cortex exhibit distinct responses in reward and strategy-update in a risk-based decision-making task

Diet-induced obesity causes hypothalamic neurochemistry alterations in Swiss mice

Behavioral and electrophysiological brain effects of aspartame on well-nourished and malnourished rats

Fucoxanthin prevents lipopolysaccharide-induced depressive-like behavior in mice via AMPK- NF-κB pathway

Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action

Acute stress response to a cognitive task in patients with major depressive disorder: potential metabolic and proinflammatory biomarkers